The second part of the HIV series covers everything that happened after the virus was discovered: the intense stigma of the early years, the US government's years of inaction under Reagan and the activism that drove the development of treatments and public awareness. Florian Krammer explains how a near-certain death sentence became a manageable chronic condition, what PrEP is and how it works, and how a handful of people (the "Berlin patients") were actually cured of HIV. The episode closes with the current situation: why UNAIDS estimates that the withdrawal of US funding could lead to millions of additional infections and deaths worldwide.

Information about PrEP by the US CDC: https://www.cdc.gov/hiv/prevention/prep.html

US CDC information about lenacapavir: https://www.cdc.gov/mmwr/volumes/74/wr/mm7435a1.htm

General US CDC Information about HIV: https://www.cdc.gov/hivnexus/hcp/guidelines/index.html

+++++

You can support the podcast via our German Steady page:

Questions, feedback or topic suggestions?

+++++

Krammer laboratory information

Krammer Laboratory at the Icahn School of Medicine at Mount Sinai

Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness

Ignaz Semmelweis Institute

+++++

Conflict of interest statement

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.

I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).

My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.

My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.

My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.